Effects of Mesenchymal Stem Cell Secretome on Cardiac Histopathological Changes in Doxorubicin-Induced Rats

Liza Aulia Putri; Dedy Syahrizal; Fauzul Husna; Muhammad Ridwan; Sri Fitriyani

doi:10.24198/ijpst.v13i1.69258

Effects of Mesenchymal Stem Cell Secretome on Cardiac Histopathological Changes in Doxorubicin-Induced Rats

Liza Aulia Putri, Dedy Syahrizal, Fauzul Husna, Muhammad Ridwan, Sri Fitriyani

Abstrak

Doxorubicin is an anthracycline chemotherapeutic agent widely used in clinical practice, but its application is limited by cardiotoxicity that damages myocardial structure and function. Mesenchymal stem cell secretome contains diverse bioactive molecules, including cytokines, growth factors, and extracellular vesicles, which contribute to tissue protection and cellular repair. This study aimed to evaluate the preventive and curative effects of secretome administration on histopathological changes in the hearts of doxorubicin-induced rats. Twenty-four rats were divided into four groups: without treatment (KS), cardiotoxicity group (KK), preventive secretome (P1), and curative secretome (P2). Histopathological assessment included degeneration, inflammatory infiltration, congestion, and necrosis using semi-quantitative scoring. Results showed no significant differences in degeneration, inflammatory infiltration, or congestion among groups. In contrast, necrosis scores differed significantly (p = 0.002), with the highest values observed in the KK group. Secretome administration in the P2 group demonstrated the most pronounced improvement, reflected by a greater reduction in necrosis scores compared to other groups. In conclusion, curative-phase secretome treatment provided the most effective histological improvement by reducing myocardial necrosis, indicating a stronger tissue repair response than preventive administration.

Kata Kunci

Cardiotoxicity; COX-2; Caspase-3; Doxorubicin; Mesenchymal Stem Cell; Secretome

Teks Lengkap:

PDF (English)

Referensi

Iqubal A, Haque SE, Sharma S, Ansari MA, Khan V, Iqubal MK, et al. CLINICAL UPDATES ON DRUG - INDUCED CARDIOTOXICITY. 2018;9(1):16–26.

Kourek C, Touloupaki M, Rempakos A, Loritis K, Tsougkos E, Paraskevaidis I, et al. Cardioprotective Strategies from Cardiotoxicity in Cancer Patients : A Comprehensive Review. J Cardiovasc Dev Dis. 2022;9(259):1–15.

Zeiss CJ, Gatti DM, Toro-salazar O, Davis C, Lutz CM, Spinale F, et al. Doxorubicin-Induced Cardiotoxicity in Collaborative Cross ( CC ) Mice Recapitulates Individual Cardiotoxicity in Humans. G3. 2019;9(August):2637–46.

Firdaus N SS. Evaluasi penggunaan kemoterapi pada pasien kanker payudara di Rumah Sakit Islam Sultan Agung Semarang periode 2022. J Ilmu Farm dan Farm Klin. 2023;20(2):155-63.

Todoerti K, Ronchetti D, Puccio N, Silvestris I, Favasuli V, Amodio N, et al. Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma. Cancers (Basel). 2021;13(5518):1–14.

Gent DG, Dobson R. Cardio-oncology The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus 2022 ESC Cardio-oncology Guidelines in Focus. 2023;

Singla SAA and DK. Mesenchymal Stem Cell-Derived Exosomes Ameliorate. Pharmaceuticals. 2024;17(93):1–15.

Chen L, Xia W, Hou M. Mesenchymal stem cells attenuate doxorubicin ‑ induced cellular senescence through the VEGF / Notch / TGF ‑ β signaling pathway in H9c2 cardiomyocytes. 2018;674–84.

Kulesza A, Paczek L, Hoffman F. The Role of COX-2 and PGE2 in the Regulation of Immunomodulation and Other Functions of Mesenchymal Stromal Cells. Iqubal A, Haque SE, Sharma S, Ansari MA, Khan V, Iqubal MK, a. 2023;11(445):1–21.

Pascasarjana P, Klinik F, Farmasi F, Mada UG, Farmakologi D, Farmasi D, et al. Narative Review : Kejadian Dan Mekanisme Kardiotoksisitas Pada Pasien Kanker Payudara Setelah Penggunaan Trastuzumab. Maj Farm. 2024;20(3):349–57.

Kundu D, Shin SY, Chilian WM. The Potential of Mesenchymal Stem Cell-Derived Exosomes in Cardiac Repair. Int J Mol Sci. 2024;25(13494):1–35.

Chaulin AM. The Essential Strategies to Mitigate Cardiotoxicity Caused by Doxorubicin. Life. 2023;13(2148):1–19.

Shamseldeen AM, Hosny SA, Maghib K, Ashour H. therapeutic enhancement. World J Stem Cells 2. 2025;17(8):1–30.

Abid AI, Conzatti G, Toti F, Anton N, Vandamme T. Nanomedicine : Nanotechnology , Biology , and Medicine Mesenchymal stem cell-derived exosomes as cell free nanotherapeutics and nanocarriers. Nanomedicine Nanotechnology, Biol Med [Internet]. 2024;61(June):102769. Available from: https://doi.org/10.1016/j.nano.2024.102769

Zhang H, Pan J, Huang S, Chen X, Chia A, Chang Y, et al. Redox Biology Hydrogen sulfide protects cardiomyocytes from doxorubicin-induced ferroptosis through the SLC7A11 / GSH / GPx4 pathway by Keap1 S-sulfhydration and Nrf2 activation. Elsevier. 2024;70(January):1–17.

Billur D, Aktay I, Bayram P, Bitirim CV, Turan B, Morphological B. Morphological and Functional Analysis of Cardiac Ameliorations in Elderly Rats Supplemented with a Magnolol Extract Complex. Int J Morphol. 2023;41(3):915–25.

Widiana, I. G. R. (2019). Aplikasi Statistik pada Penelitian Kedokteran. Jakarta: Penerbit HVS (EGC). ix + 230 hal. ISBN 979-044-697-7.

Hamada, C. Statistical Analysis for Toxicity Studies. J Toxicol Pathol. 2018;31:15-22.

Podyacheva E, Shmakova T, Kushnareva E, Onopchenko A. Modeling Doxorubicin-Induced Cardiomyopathy With Fibrotic Myocardial Damage in Wistar Rats. Cardiol Res [Internet]. 2022;13(6):339–56. Available from: https://www.doi.org/10.14740/cr1416

Wang T, Xing G, Fu T, Ma Y, Wang Q, Zhang S, et al. Role of mitochondria in doxorubicin-mediated cardiotoxicity : from molecular mechanisms to therapeutic strategies. Int J Med Sci. 2024;21.

Kundu D, Shin SY, Chilian WM. The Potential of Mesenchymal Stem Cell-Derived Exosomes in Cardiac Repair. Int J Mol Sci. 2024;25(13494):1–35.

Marrow B, Stem M, Lei B, Wu X, Xia K, Sun H, et al. Induced Myocardial. J Am Hear Assoc. 2021;10(e020589):1–20.

Ji Z, Wang C. Mesenchymal stem cell-derived exosomal mir- 21-5p inhibits YAP1 expression and improves outcomes in myocardial infarction. Ji Wang BMC Cardiovasc Disord. 2024;24(547):1–15.

Piotrowska P, Kraskiewicz H. Mesenchymal Stem Cell Secretome for Cardiac Regeneration : Opportunity for Cell-Free Therapy. Int J Mol Sci. 2026;27(209):1–20.

Stonebrook E, Hoff M, Spencer JD. Congenital Anomalies of the Kidney and Urinary Tract: A Clinical Review. Curr Treat Options Pediatr. 2020;5(3):223–35.

Gong Z ting, Xiong Y yan, Ning Y, Tang R jie, Xu J yan, Jiang W yang, et al. Nicorandil-Pretreated Mesenchymal Stem Cell-Derived Exosomes Facilitate Cardiac Repair After Myocardial Infarction via Promoting Macrophage M2 Polarization by Targeting miR-125a-5p / TRAF6 / IRF5 Signaling Pathway. Int J Nanomedicine. 2024;19:2005–24.

Feng Y, Bao X, Zhao J, Kang L, Sun X, Xu B. MSC-Derived Exosomes Mitigate Myocardial Ischemia / Reperfusion Injury by Reducing Neutrophil Infiltration and the Formation of Neutrophil Extracellular Traps. Int J Nanomedicine Publ. 2024;19:2071–90.

DOI: https://doi.org/10.24198/ijpst.v13i1.69258